The good response of non‐smoker NSCLC patients to EGFR TKIs is associated with activating EGFR mutations (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.